Table 2.
Response rates at the end of treatment and sustained response after one year of follow up
| Response rate | Group A (IFN+riba) (n=44) | Group B (IFNi+riba) (n=46) | Group C (IFNi+riba+ama) (n=24) | Group C minus group A and B rate (95% CI) | p Value* |
| End of treatment (overall) | 11 (25%) | 13 (29%) | 16 (67%) | 40% (19–61%) | 0.001 |
| HCV genotype 1 | 26% (6/31) | 30% (10/33) | 53% (9/17) | 28% (3–53%) | 0.054 |
| HCV genotype non-1 | 23% (5/13) | 23% (3/13) | 100% (7/7) | 70% (29–111%) | 0.004 |
| Chronic hepatitis | 33% (11/33) | 38% (13/34) | 69% (11/16) | 33% (6–60%) | 0.034 |
| Cirrhosis | 0% (0/11) | 0% (0/12) | 62.5% (5/8) | 62% (33–92%) | 0.001 |
| One year follow up (overall) | 1 (2%) | 2 (4%) | 6 (25%) | 22% (10–34%) | 0.002 |
| HCV genotype 1 | — | 3% (1/33) | 12% (2/17) | ||
| HCV genotype non-1 | 8% (1/13) | 8% (1/13) | 57% (4/7) | ||
| Chronic hepatitis | 3% (1/33) | 6% (2/34) | 31% (5/16) | ||
| Cirrhosis | — | — | 12.5% (1/8) |
*Group C versus groups A and B.
IFN, interferon; IFNi, interferon induction; riba , ribavirin; ama, amantadine; HCV, hepatitis C virus.